Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

SMMT's Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab's development beyond the NSCLC indication.

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter ...

Florida, USA-based Summit Therapeutics saw its share rise 6.2% to $23.50 pre-market on the news of a clinical trial ...

Robert Duggan; Executive Chairman of the Board, Co-Chief Executive Officer; Summit Therapeutics Inc Mahkam Zanganeh; President, Co-Chief Executive Officer, Director; Summit Therapeutics Inc Manmeet ...

Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...

Summit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...

Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results support ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Summit Therapeutics sank -13.4% today, compared to the S&P 500's day change of -0.0%. Today's losers may turn out to be ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...